CL2024002422A1 - Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos - Google Patents

Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos

Info

Publication number
CL2024002422A1
CL2024002422A1 CL2024002422A CL2024002422A CL2024002422A1 CL 2024002422 A1 CL2024002422 A1 CL 2024002422A1 CL 2024002422 A CL2024002422 A CL 2024002422A CL 2024002422 A CL2024002422 A CL 2024002422A CL 2024002422 A1 CL2024002422 A1 CL 2024002422A1
Authority
CL
Chile
Prior art keywords
targeting
compounds
radioligands
solvate
compositions
Prior art date
Application number
CL2024002422A
Other languages
English (en)
Spanish (es)
Inventor
Liu Fa
Original Assignee
Full Life Tech Hk Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Full Life Tech Hk Limited filed Critical Full Life Tech Hk Limited
Publication of CL2024002422A1 publication Critical patent/CL2024002422A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CL2024002422A 2022-02-18 2024-08-13 Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos CL2024002422A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202263311621P 2022-02-18 2022-02-18

Publications (1)

Publication Number Publication Date
CL2024002422A1 true CL2024002422A1 (es) 2024-12-06

Family

ID=87579080

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2024002422A CL2024002422A1 (es) 2022-02-18 2024-08-13 Compuestos y radioligandos para dirección al receptor de neurotensina y usos de los mismos

Country Status (11)

Country Link
US (2) US12145926B2 (enExample)
EP (1) EP4479040A1 (enExample)
JP (1) JP2025506705A (enExample)
KR (1) KR20240150464A (enExample)
CN (1) CN119136796A (enExample)
AU (1) AU2023221977A1 (enExample)
CA (1) CA3243418A1 (enExample)
CL (1) CL2024002422A1 (enExample)
IL (1) IL314786A (enExample)
MX (1) MX2024009858A (enExample)
WO (1) WO2023158802A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023158802A1 (en) 2022-02-18 2023-08-24 Full-Life Technologies U.S. Inc. Compounds and radioligands for targeting neurotensin receptor and uses thereof
WO2025146126A1 (en) * 2024-01-04 2025-07-10 Full-Life Technologies Hk Limited Preparation method of compounds targeting neurotensin receptor
JP2026106435A (ja) * 2024-12-17 2026-06-29 イーライ リリー アンド カンパニー ニューロテンシン受容体リガンド

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5021556A (en) 1987-07-22 1991-06-04 Neorx Corporation Method of radiolabeling chelating compounds comprising sulfur atoms with metal radionuclides
US5075099A (en) 1988-05-31 1991-12-24 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5364613A (en) 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5367080A (en) 1990-11-08 1994-11-22 Sterling Winthrop Inc. Complexing agents and targeting radioactive immunoreagents useful in therapeutic and diagnostic imaging compositions and methods
DE4307983A1 (de) 1993-03-13 1994-09-15 Beiersdorf Ag Wirkstoffe und kosmetische und dermatologische Zubereitungen
FR2732967B1 (fr) 1995-04-11 1997-07-04 Sanofi Sa 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
US5886142A (en) 1997-05-20 1999-03-23 Thomas Jefferson University Radiolabeled thrombus imaging agents
EP2740726A1 (en) * 2012-12-07 2014-06-11 3B Pharmaceuticals GmbH Neurotensin receptor ligands
CA2949936C (en) 2014-06-10 2022-10-18 3B Pharmaceuticals Gmbh Conjugate comprising a neurotensin receptor ligand and use thereof
EP3279197A1 (en) 2016-08-03 2018-02-07 Friedrich-Alexander-Universität Erlangen-Nürnberg Diagnosis, treatment and prevention of neurotensin receptor-related conditions
WO2023158802A1 (en) 2022-02-18 2023-08-24 Full-Life Technologies U.S. Inc. Compounds and radioligands for targeting neurotensin receptor and uses thereof

Also Published As

Publication number Publication date
IL314786A (en) 2024-10-01
WO2023158802A1 (en) 2023-08-24
CA3243418A1 (en) 2023-08-24
US20240287046A1 (en) 2024-08-29
AU2023221977A1 (en) 2024-08-15
KR20240150464A (ko) 2024-10-15
US20250026739A1 (en) 2025-01-23
EP4479040A1 (en) 2024-12-25
MX2024009858A (es) 2024-11-08
US12145926B2 (en) 2024-11-19
CN119136796A (zh) 2024-12-13
JP2025506705A (ja) 2025-03-13

Similar Documents

Publication Publication Date Title
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
MX2024009858A (es) Compuestos y radioligandos para direccion al receptor de neurotensina y usos de los mismos
CL2024001560A1 (es) Radioligandos escindibles para dirigirse a receptores de la superficie celular y usos de los mismos.
BR112023026747A2 (pt) Métodos e composições para direcionamento de pd-l1
CO2021013927A2 (es) Protacs que degradan el receptor de estrógeno
MX2021008976A (es) Inhibidores marcados de antigeno prostatico especifico de membrama (psma), su uso como agentes formadores de imagenes y agentes farmaceuticos para el tratamiento de cancer de prostata.
RU2011139107A (ru) Специфические соединения диарилгидантоина и диарилтиогидантоина
MX2019014368A (es) Agentes de imagenologia nuevos para tomografia de emision de positrones (pet) sustituidos con deuterio y su aplicacion farmacologica.
CL2008002768A1 (es) Compuestos derivados de carboxiciclopropil-(bis-fenil-oxamidas); composicion farmaceutica que los contiene; procedimiento para la elaboracion de las composiciones y el uso de los compuestos en el tratamiento de diabetes y trastornos del sncentre otras enfermedades.
PH12020551471A1 (en) Psma-targeted radiopharmaceutical for diagnosing and treating prostate cancer
CL2020001097A1 (es) Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6.
UY36207A (es) Inhibidores de la syk
AR125209A1 (es) Compuestos anticancerígenos dirigidos a los receptores de hormonas nucleares
CO2019010029A2 (es) Compuestos de tipo imidazo[4,5-c]quinolin-2-ona deuterados y su uso en el tratamiento del cáncer
CO2020005944A2 (es) Compuestos heterocíclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y métodos de síntesis de los mismos
AR132362A1 (es) Conjugados que comprenden enlazadores escindibles
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
MX2024010104A (es) Compuesto bicíclico condensado que contiene pirrolinona.
CO2025003099A2 (es) Compuestos para el tratamiento del cáncer
DOP2022000073A (es) Derivados de 2-azaspiro[3,4]octano como agonistas de m4
ECSP22040362A (es) Derivados de 1,2,4–oxadiazol como agonistas del receptor hepático x
MX2026000307A (es) Ligando de proteina para la activacion de fibroblastos y su uso
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
DOP2022000075A (es) Derivados de 2–azaespiro[3.4]octano como agonistas de m4
CO2025007339A2 (es) Compuesto bicíclico fusionado